BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies

BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. More recently, the combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown improved progression-free...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Spagnolo, Francesco, Ghiorzo, Paola, Orgiano, Laura, Pastorino, Lorenza, Picasso, Virginia, Tornari, Elena, Ottaviano, Vincenzo, Queirolo, Paola
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4303458/
https://ncbi.nlm.nih.gov/pubmed/25653539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S39096
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky